Subsequently, this group incorporated this potent inhibitor into CRBN‐based PROTACs, obtaining a potent degrader, QCA570 (35), which degraded BRD4 and inhibited cell growth in AML cell lines with picomolar potency (IC50 values between 8.3 and 32 pM), being 1000 times more potent than dBET1 in all cell lines tested.131. The gene discussed is BRD4; the disease is acute myeloid leukemia.